Clinical Trial Update: An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder [Phase 3]

View source ↗

Summary

This update reports the results of a Phase 3 eight-week trial evaluating the efficacy and safety of SR58611A in adults with generalized anxiety disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• SR58611A

Snippet

Sponsor: Sanofi | Conditions: Anxiety Disorders | Phase 3 | Status: COMPLETED